Aptamer-Based ADAPT Platform from Caris Life Sciences Detects Breast Cancer in Women via Liquid Biopsy of Circulating Exosomes

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced, on February 21, 2017, the results of a study that demonstrates the ability of the company’s ADAPT Biotargeting System™ to detect and classify women with or without breast cancer based on a minimally-invasive liquid biopsy of circulating exosomes from blood plasma. The study was published in Nature’s Scientific Reports (http://www.nature.com/articles/srep42741) on February 20. The open-access article is titled “Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach.” “The ability to accurately detect breast cancer with a minimally-invasive blood-based method that covers a systems-wide range of biomarkers would offer a significant advance in breast cancer diagnosis and patient management,” said Dr. Lee Schwartzberg (not involved in the research), Chief, Division of Hematology/Oncology at the University of Tennessee Health Science Center. “Results of this study provide a potential future opportunity to address shortcomings in the current standard of diagnostic testing utilizing mammography and other imaging techniques, which frequently generate indeterminate results that can result in patients facing invasive tissue biopsies.” The ADAPT Biotargeting System uses a highly complex library of single-stranded molecules called oligodeoxynucleotide (ssODNs) aptamers that bind to individual and multi-component targets, enabling them to profile biological samples at a systems-wide scale. In the study published in Scientific Reports, a parent library of approximately 1011 ssODNs was “trained,” or enriched, for aptamers that preferentially associate either with plasma exosomes from women with breast cancer or with plasma exosomes from women without breast cancer.
Login Or Register To Read Full Story